6月25日 - ** 药物开发商Plus Therapeutics PSTV.O股价上涨一倍多，达到38美分
** 该公司称，美国食品和药物管理局（FDA）已批准其申请，开始对其实验性脑癌疗法进行人体试验。
** 该公司称，美国国防部为这项试验提供了 300 万美元的研究经费。
** 早期试验的目的是确定名为 Reyobiq 的疗法在 6 至 21 岁儿童患者中的最大耐受剂量安全性和耐受性。
** 该公司正在测试该疗法，以治疗侵袭性脑肿瘤，即高级别胶质瘤和脑外膜瘤。
** 包括盘中走势在内，该股今年累计下跌 68.1%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.